SBBP News and Press, Strongbridge Biopharma plc From 03/22/21

Support.com (SPRT) +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU) +17% as Canadian Pacific to buy the company fo...

~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~ ~ Strongbridge Recently Submitted a New Drug Application (NDA) for RECORLEV ® (levoketoconazole) to the U.S. Food & Drug Administration ~ DUBLIN, Ireland and TREVOS...

SenesTech (SNES) +83% on successful completion of a long term agricultural deployment of ContraPest®ZK International Group (ZKIN) +31%.Marker Therapeutics (MRKR) +28% as as Cantor initiates with high target and insider buying.Clovis Oncology (CLVS) +20% as ARIEL4 study met...

DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...

Strongbridge Biopharma plc (SBBP) Q4 2020 Earnings Conference Call March 03, 2021, 08:30 AM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - Chief Executive Officer Fredric Cohen - Chief Medical Officer Richard Kollender - Chief Financial Officer and Chie...

The following slide deck was published by Strongbridge Biopharma plc in conjunction with their 2020 Q4 earnings call. For further details see: Strongbridge Biopharma plc 2020 Q4 - Results - Earnings Call Presentation

Strongbridge Biopharma (SBBP): Q4 Non-GAAP EPS of -$0.11 in-line; GAAP EPS of -$0.18 misses by $0.05.Revenue of $8.23M (+46.7% Y/Y) beats by $0.03M.Reports $87.5 Million in Cash on Hand; Expects to Fund Operations Into and Potentially Beyond the First Quarter of 2023 ~Press Release For furt...

~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to U.S. Food & Drug Administration ~ ~ KEVEYIS® (dichlorphenamide) Full-Year 2020 Revenue of $30.7 Million, a 41.5 Percent Increase ove...

~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~ ~ Nearly 40 Percent of Prescription-Treated Endogenous Cushing’s Syndrome Patients in t...

DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...